Clinical Trial

Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).

Study acronym: CON-PO
Recruiting
View on ClinicalTrials.gov →
Summary
Asthma affects the lower respiratory tract (bronchi), whereas chronic rhinosinusitis with nasal polyposis (CRSwNP) involves the upper airways. Despite this anatomical distinction, the upper and lower airways form a continuous respiratory tract and share common pathophysiological mechanisms. Consequently, asthma and CRSwNP frequently coexist, and several therapeutic strategies are effective for both conditions. Given these overlaps, we hypothesize that a multidisciplinary consultation involving both a pulmonologist and an ENT specialist could be more effective than separate consultations for patient care. We also believe that this innovative organization that would benefit the healthcare system. To test this hypothesis, we are conducting a study whose primary objective is to assess whether joint consultations lead to a reduction in oral corticosteroid need over the year following the initial consultation, by enabling more personalized treatment strategies. Secondary outcomes will include the frequency of asthma exacerbations, frequency of ENT-related events, respiratory symptoms, quality of life, and healthcare ressources utilization. We will compare outcomes between two patient groups: one receiving joint consultation from both specialists, and the other managed through standard, separate consultations as per current clinical practice.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-04
notable Primary completion pushed: 2028-11 -> 2029-11 2026-08-04
minor Completion pushed: 2028-11 -> 2029-11 2026-08-04
Trial Details
NCT Number NCT07134686
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 195 participants
Start Date 2026-07-28
Primary Completion 2029-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03